Pharmacokinetics of once-daily lopinavir/ritonavir and the influence of dose modifications.
We studied the pharmacokinetics of lopinavir/ritonavir dosed at 800/200 mg a day in 20 HIV-1-infected patients, and evaluated the effect of dose modifications in the case of trough concentration (Ctrough) levels less than 1.0 mg/l. Ctrough levels after the daily administration of lopinavir/ritonavir were lower than with twice daily administration. Dose modifications in four patients with Ctrough levels less than 1.0 mg/l succeeded in only one patient. Therapeutic drug monitoring can identify patients with lower-than-expected lopinavir exposure in a larger study.
la Porte
Charles J L
CJ
Department of Clinical Pharmacy, Radboud University Medical Centre, Nijmegen, The Netherlands.
Schippers
Emile F
EF
van der Ende
Marchina E
ME
Koopmans
Peter P
PP
Blok
Willem L
WL
Kauffmann
Robbert H
RH
Kroon
Frank P
FP
Burger
David M
DM
D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000493:pharmacokinetics*; D006801:Humans; D061466:Lopinavir; D008297:Male; D011744:Pyrimidinones / Q000008:administration & dosage / Q000493:pharmacokinetics*; D019438:Ritonavir / Q000008:administration & dosage / Q000493:pharmacokinetics*
D004338:Drug Combinations; D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D061466:Lopinavir; D019438:Ritonavir